Literature DB >> 8625174

Nourishment of hepatocellular carcinoma cells through the portal blood flow with and without transcatheter arterial embolization.

N Goseki1, T Nosaka, M Endo, M Koike.   

Abstract

BACKGROUND: Although transcatheter arterial embolization (TAE) for hepatocellular carcinoma (HCC) is very effective, local recurrence is not so rare. The reason is thought to be related to portal blood flow. The changes in the nourishing vessels in HCC after TAE were examined from the viewpoint of cell kinetics with direct reference to intracellular transportation of biochemical substrates, namely 5 bromo-2'-deoxyuridine (BrdU), an analogue of thymidine.
METHODS: To examine the cell kinetics of carcinoma cells, BrdU was infused intraoperatively in 23 patients with HCC (12 without TAE and 11 post-TAE patients) directly into the portal branch feeding the region to be resected. Specimens were prepared for immunohistochemical staining using BrdU monoclonal antibodies and analyzed using the labeling index (LI). The distribution of the labeled S-phase cell was also examined.
RESULTS: The LI in post-TAE patients was about six times higher than patients without TAE, with a significant difference at P < 0.001. Labeled cells were distributed not only peripherally but in the central part of the tumor, although the number was extremely small.
CONCLUSIONS: Some HCC cells, although small in number, are nourished by the portal blood flow directly throughout the viable tumor mass, which may act as the main blood supplier during the period after TAE. For greater local control of HCC, complete resection of HCC and/or the use of chemotherapy via not only the hepatic artery but also the portal blood flow are beneficial.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8625174     DOI: 10.1002/1097-0142(19950901)76:5<736::aid-cncr2820760505>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Hepatic perfusion changes after transcatheter arterial embolization (TAE) of hepatocellular carcinoma: measurement by dynamic computed tomography (CT).

Authors:  Y Tsushima; Y Unno; J Koizumi; S Kusano
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

2.  Cytotoxic activity of anticancer drugs on hepatocellular carcinoma cells in hypoxic-hyponutritional culture.

Authors:  Qiang Li; Lin-Zhong Zhu; Ren-Jie Yang; Xu Zhu
Journal:  Int Surg       Date:  2014 Nov-Dec

3.  Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection.

Authors:  Qingfeng Song; Weizheng Ren; Liwei Fan; Meiqi Zhao; Lisha Mao; Shichai Jiang; Chang Zhao; Ying Cui
Journal:  Dig Dis Sci       Date:  2019-07-17       Impact factor: 3.199

4.  Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

Authors:  Masao Omata; Laurentius A Lesmana; Ryosuke Tateishi; Pei-Jer Chen; Shi-Ming Lin; Haruhiko Yoshida; Masatoshi Kudo; Jeong Min Lee; Byung Ihn Choi; Ronnie T P Poon; Shuichiro Shiina; Ann Lii Cheng; Ji-Dong Jia; Shuntaro Obi; Kwang Hyub Han; Wasim Jafri; Pierce Chow; Seng Gee Lim; Yogesh K Chawla; Unggul Budihusodo; Rino A Gani; C Rinaldi Lesmana; Terawan Agus Putranto; Yun Fan Liaw; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2010-03-18       Impact factor: 6.047

5.  Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization.

Authors:  Eun Sun Jang; Jung-Hwan Yoon; Jin Wook Chung; Eun Ju Cho; Su Jong Yu; Jeong-Hoon Lee; Yoon Jun Kim; Hyo-Suk Lee; Chung Yong Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-03       Impact factor: 4.553

6.  Yttrium-90 Portal Vein Radioembolization in Sprague-Dawley Rats: Dose-Dependent Imaging and Pathological Changes in Normal Liver.

Authors:  Andrew C Gordon; Sarah B White; Vanessa L Gates; Weiguo Li; Daniel Procissi; Zhuoli Zhang; Kathleen R Harris; Dong-Hyun Kim; Samdeep K Mouli; Reed A Omary; Riad Salem; Andrew C Larson; Robert J Lewandowski
Journal:  Cardiovasc Intervent Radiol       Date:  2020-08-16       Impact factor: 2.740

7.  Suppressing DRP1-mediated mitochondrial fission and mitophagy increases mitochondrial apoptosis of hepatocellular carcinoma cells in the setting of hypoxia.

Authors:  Xia-Hui Lin; Bai-Quan Qiu; Min Ma; Rui Zhang; Shu-Jung Hsu; Hua-Hua Liu; Jun Chen; Dong-Mei Gao; Jie-Feng Cui; Zheng-Gang Ren; Rong-Xin Chen
Journal:  Oncogenesis       Date:  2020-07-13       Impact factor: 7.485

8.  Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization.

Authors:  Kittipitch Bannangkoon; Keerati Hongsakul; Teeravut Tubtawee; Teerha Piratvisuth
Journal:  Clin Mol Hepatol       Date:  2019-02-28

Review 9.  Ultraselective conventional transarterial chemoembolization: When and how?

Authors:  Shiro Miyayama
Journal:  Clin Mol Hepatol       Date:  2019-04-26

Review 10.  Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma.

Authors:  Ching-Tso Chen; Tsung-Hao Liu; Yu-Yun Shao; Kao-Lang Liu; Po-Chin Liang; Zhong-Zhe Lin
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.